Your email has been successfully added to our mailing list.

×
0.126903553299492 0.126903553299492 0.126903553299492 0.126903553299492 0.126903553299492 0.126903553299492 0.0829103214890017 0.065989847715736
Stock impact report

Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy

ACHISON INC A (ACHN) 
Last achison inc a earnings: 11/7 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.achillion.com/investor-relations
Company Research Source: GlobeNewswire
NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the complement alternative pathway, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on ACH-4471 for orphan status in the European Union (EU) for the treatment of C3 glomerulopathy (C3G). “We are very pleased that ACH-4471, a first-in-class, oral inhibitor of complement factor D, has received a positive orphan status opinion for the treatment of C3G. At Achillion, we continually work to enhance the awareness of C3G, a rare renal disorder consisting of dense deposit disease (C3G) and C3 glomerulonephritis (C3GN) for which there are no approved therapies,” commented Milind Deshpande, Ph.D., Chief Executive Officer of Achillion. Dr. Deshpande further stated, “The mechanism of action for our factor D inhibitors, Show less Read more
Impact Snapshot
Event Time:
ACHN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ACHN alerts
Opt-in for
ACHN alerts

from News Quantified
Opt-in for
ACHN alerts

from News Quantified